Explore All 2731 Add-on Acquisition Medical Products Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | September 27, 2010 |
| Target | Micrus Endovascular |
| Sector | Medical Products |
| Buyer(s) | Johnson & Johnson |
| Sellers(s) | Invision |
| Deal Type | Add-on Acquisition |
| Deal Value | 480M USD |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1886 |
| Sector | Consumer Products |
| Employees | 132,000 |
| Revenue | 88.8B USD (2024) |
Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.
| Deal Context for Buyer | # |
|---|---|
| Overall | 22 of 47 |
| Sector: Medical Products | 12 of 17 |
| Type: Add-on Acquisition | 17 of 39 |
| State: California | 8 of 15 |
| Country: United States | 19 of 39 |
| Year: 2010 | 1 of 2 |
| Size (of disclosed) | 24 of 31 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-05-31 |
Cougar Biotechnology
Raritan, New Jersey, United States Cougar Biotechnology (CGRB) is a biotechnology company established to in-license and develop oncology drugs. Cougar's oncology portfolio includes CB7630, a targeted enzyme inhibitor, which is currently being tested in Phase II clinical trials in prostate cancer; other products are being tested for hematological and solid tumors. |
Buy | $1.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-10-06 |
Crucell NV
Leiden, Netherlands Crucell NV is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 400M EUR |
| Size | Middle-Market |
| Type | Sector Agnostic |
Invision AG is a private equity firm focused on growth capital investments in European companies or companies with opportunities in Europe. Target sectors include information technology, software, electronics, telecommunications, medical devices, healthcare services, financial services, and media. Invision looks to invest between €20 and €100 million in businesses generating €25 and €200 million in sales. Invision was formed in 1996 as the corporate venture capital arm of Metro Holding. Invision is based in Zug, Switzerland.
| Deal Context for Seller | # |
|---|---|
| Overall | 15 of 24 |
| Sector: Medical Products | 2 of 2 |
| Type: Add-on Acquisition | 5 of 8 |
| State: California | 4 of 4 |
| Country: United States | 7 of 7 |
| Year: 2010 | 1 of 1 |
| Size (of disclosed) | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-07-09 |
Valista
Kilmacanogue, Ireland Valista, Ltd. is the provider of payment software for the purchase of premium services. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-07-29 |
Datamars
Lamone, Switzerland Datamars is a provider of electronic tagging systems for the pet, livestock, and textile industries. Datamars provide complete systems tuned to deliver optimized performance in a range of vertical segments: professional laundries, animal identification, and other industries where identification in critical environment conditions is necessary. Datamars was founded in 1988 and is based in Lamone, Switzerland. |
Sell | - |
